Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2021

Revenue From Contract With Customer [Abstract]

Schedule of Timing of Revenue Recognition

The following table illustrates the timing of the Company’s revenue recognition:

	Year Ended December 31,
	2021			2020			2019
Software products and services – point in time		55.5	%		55.0	%		49.9	%
Software products and services – over time		26.6			30.6			28.1
Drug Discovery – point in time		3.3			6.7			8.6
Drug Discovery – over time		14.6			7.7			13.4

Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue

The following table presents the revenue recognized from the sources of software products and services revenue:

	Year Ended December 31,
	2021		2020		2019
On-premise software	$	74,598	$	58,311	$	42,647
Hosted software		11,076		9,192		7,418
Software maintenance		17,294		14,465		11,643
Professional services		9,268		9,562		5,027
Revenue from contracts with customers		112,236		91,530		66,735
Software contribution		1,000		1,000		—
Total software revenue	$	113,236	$	92,530	$	66,735

Drug Discovery Revenue

	Year Ended December 31,
	2021		2020		2019
Drug discovery services revenue from contracts with customers	$	24,584	$	15,565	$	18,808
Drug discovery contribution		111		—		—
Total drug discovery revenue	$	24,695	$	15,565	$	18,808

Schedule of Contract Balances

Contract balances were as follows:

	As of December 31,		As of December 31,
	2021		2020
Contract assets	$	8,271	$	3,589
Deferred revenue, short-term:
Software products and services		32,945		28,218
Drug discovery		22,423		17,185
Deferred revenue, long-term:
Software products and services		3,938		1,976
Drug discovery		26,126		39,188